Compositions and methods for enriching photoreceptors

By employing JAM-B, CD26, and CD133 binding agents to enrich photoreceptor cells from mixed populations, the method addresses yield and purity challenges, achieving high-purity photoreceptor cell grafts for treating ocular disorders.

WO2026099504A1 Publication Date: 2026-05-15TENPOINT THERAPEUTICS LTD
9 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/082614
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-11
Filing Date
2025-11-11
Publication Date
2026-05-15

AI Technical Summary

Technical Problem

Current methods for producing functional photoreceptor cells, particularly cone photoreceptors, from stem cell-derived retinal organoids face challenges in yield and purity, and the isolation of photoreceptors from mixed cell populations is hindered by the presence of non-photoreceptor cells, which can affect graft survival and integration.

Method used

The use of JAM-B, CD26, and CD133 binding agents, such as antibodies or nanobodies, to enrich photoreceptor and photoreceptor precursor cells from mixed populations through techniques like FACS and MACS, allowing for the separation of these cells based on specific cell surface markers.

Benefits of technology

This method achieves a significant enrichment of photoreceptor cells, with populations comprising at least 80-95% purity, enhancing the viability and integration potential of grafts for treating ocular disorders like IRDs, AMD, and GA.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are methods of enriching for photoreceptors and photoreceptor precursor cells from mixed cell populations. Such enriched populations of photoreceptors and photoreceptor precursor cells can be used as cell therapies for the treatment of retinal disorders.
Need to check novelty before this filing date? Find Prior Art